Inhalation Sciences Sweden Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Inhalation Sciences Sweden ha un patrimonio netto totale di SEK13.0M e un debito totale di SEK1.1M, che porta il suo rapporto debito/patrimonio netto a 8.4%. Le sue attività totali e le sue passività totali sono rispettivamente SEK18.2M e SEK5.2M.

Informazioni chiave

8.4%

Rapporto debito/patrimonio netto

SEK 1.09m

Debito

Indice di copertura degli interessi	n/a
Contanti	SEK 7.83m
Patrimonio netto	SEK 12.95m
Totale passività	SEK 5.21m
Totale attività	SEK 18.17m

Aggiornamenti recenti sulla salute finanziaria

Nessun aggiornamento

Recent updates

We're Not Counting On Inhalation Sciences Sweden (NGM:ISAB) To Sustain Its Statutory Profitability

Dec 29

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( SEK15.8M ) di ISAB superano le sue passività a breve termine ( SEK4.8M ).

Passività a lungo termine: Le attività a breve termine di ISAB ( SEK15.8M ) superano le sue passività a lungo termine ( SEK442.0K ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: ISAB ha più liquidità del suo debito totale.

Riduzione del debito: Il rapporto debito/patrimonio netto di ISAB si è ridotto da 55.2% a 8.4% negli ultimi 5 anni.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: ISAB ha una pista di cassa sufficiente per più di un anno in base al suo attuale flusso di cassa libero.

Previsione Cash Runway: ISAB ha una liquidità sufficiente per 1.3 anni se il flusso di cassa libero continua a ridursi ai tassi storici del 1.5 % ogni anno.

Inhalation Sciences Sweden Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Inhalation Sciences Sweden AB (publ) to Report Nine Months, 2024 Results on Nov 20, 2024

Inhalation Sciences Sweden AB (publ) to Report Q2, 2024 Results on Aug 28, 2024

Inhalation Sciences Sweden AB (publ) to Report Q1, 2024 Results on May 28, 2024

Inhalation Sciences Sweden AB (publ), Annual General Meeting, May 14, 2024

Inhalation Sciences Sweden AB (publ) to Report Fiscal Year 2023 Results on Feb 28, 2024

Third quarter 2023 earnings released: kr0.098 loss per share (vs kr0.31 loss in 3Q 2022)

New major risk - Share price stability

Inhalation Sciences Sweden AB (publ) to Report Q3, 2023 Results on Nov 22, 2023

New major risk - Revenue and earnings growth

Inhalation Sciences Sweden AB (publ) to Report Q2, 2023 Results on Aug 29, 2023

New minor risk - Shareholder dilution

First quarter 2023 earnings released: kr0.20 loss per share (vs kr0.30 loss in 1Q 2022)

Inhalation Sciences Receives Formal Clearance to Begin the Trial of Inhalation Study

Inhalation Sciences Sweden AB (publ) to Report Fiscal Year 2022 Results on Feb 28, 2023

Third quarter 2022 earnings released: kr0.31 loss per share (vs kr0.40 loss in 3Q 2021)

No independent directors

Second quarter 2022 earnings released: kr0.36 loss per share (vs kr0.56 loss in 2Q 2021)

Inhalation Sciences Sweden AB (publ) Announces Resignation of Klaus Gottwald from Its Board of Directors

Inhalation Sciences Receives Landmark FDA Approval for Co-Financing of its Study to Validate Dissolvit as a Standard Research Method in the US

First quarter 2022 earnings: EPS and revenues miss analyst expectations

No independent directors

Full year 2021 earnings: EPS and revenues miss analyst expectations

Inhalation Sciences Sweden AB (publ), Annual General Meeting, May 06, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Inhalation Sciences Submits Whitepaper to FDA Aiming to Establish DissolvIt® as an FDA-Recommended Standard Research Method in US

Inhalation Sciences Announces Positive Study Results

Second quarter 2021 earnings released: kr0.56 loss per share (vs kr1.92 profit in 2Q 2020)

Investor sentiment improved over the past week

Inhalation Sciences Completes Enrolment in PreciseInhale Clinical Trial

Inhalation Sciences Sweden AB (Publ) Receives CTA Approval for Landmark Clinical Trial of Preciseinhale

Investor sentiment improved over the past week

First quarter 2021 earnings released: kr0.40 loss per share (vs kr0.068 profit in 1Q 2020)

Inhalation Sciences AB Provides Revenue Guidance for the Full Year of Fiscal 2021

New 90-day low: kr10.30

We're Not Counting On Inhalation Sciences Sweden (NGM:ISAB) To Sustain Its Statutory Profitability

Inhalation Sciences Appoints Paolo Raffaelli as New Chief Commercial Officer to Drive Global Sales

Market bids up stock over the past week

Inhalation Sciences Receives New Order Worth EUR 196,000 from University of Vienna

New 90-day low: kr10.80

Inhalation Sciences Announces to Successfully Installed its First Ever Commercial Version of the in Vitro Dissolvit Module at the Swiss Laboratory of a Long-Term ISAB Customer

An undisclosed buyer acquired an unknown stake in Ziccum AB (publ) (NGM:ZICC) from Inhalation Sciences Sweden AB (publ) (NGM:ISAB) for approximately SEK 21.2 million.

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane